Cara Therapeutics | CARA - Cash And Equivalent


Cara Therapeutics reported $22.28M in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 976.45M 19.97M Sep/2026
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Cara Therapeutics USD 22.28M 2.42M Sep/2026
Cassava Sciences USD 46.99M 35.69M Sep/2026
Chugai Pharma JPY 382.3B 8.13B Sep/2026
Cipla INR 16.59B 6.41B Sep/2026
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 10.28M 2.15M Jun/2026
CSL USD 2.16B 633M Jun/2025
Grifols EUR 979.78M 334.84M Dec/2024
Halozyme Therapeutics USD 1.03B 866.85M Sep/2026
J&J USD 16.91B 3.51B Sep/2026
Neurocrine Biosciences USD 641.5M 309.1M Sep/2026
Pacira USD 1.79B 1.58B Sep/2026
Pfizer USD 1.82B 848M Sep/2026
RedHill Biopharma USD 2.87M 1.75M Jun/2025
Supernus Pharmaceuticals USD 175.88M 4.07M Sep/2026
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025